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Abstract
Botulism, characterized by flaccid paralysis, commonly results from botulinum neurotoxin (BoNT) absorption across the
epithelial barrier from the digestive tract and then dissemination through the blood circulation to target autonomic and
motor nerve terminals. The trafficking pathway of BoNT/A passage through the intestinal barrier is not yet fully understood.
We report that intralumenal administration of purified BoNT/A into mouse ileum segment impaired spontaneous muscle
contractions and abolished the smooth muscle contractions evoked by electric field stimulation. Entry of BoNT/A into the
mouse upper small intestine was monitored with fluorescent HcA (half C-terminal domain of heavy chain) which interacts
with cell surface receptor(s). We show that HcA preferentially recognizes a subset of neuroendocrine intestinal crypt cells,
which probably represent the entry site of the toxin through the intestinal barrier, then targets specific neurons in the
submucosa and later (90–120 min) in the musculosa. HcA mainly binds to certain cholinergic neurons of both submucosal
and myenteric plexuses, but also recognizes, although to a lower extent, other neuronal cells including glutamatergic and
serotoninergic neurons in the submucosa. Intestinal cholinergic neuron targeting by HcA could account for the inhibition of
intestinal peristaltism and secretion observed in botulism, but the consequences of the targeting to non-cholinergic
neurons remains to be determined.
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Introduction
Botulinum neurotoxins (BoNTs) are responsible for a severe
nervous disease in man and animals known as botulism,
characterized by skeletal muscle flaccid paralysis and respiratory
arrest, resulting from inhibition of acetylcholine (ACh) release in
peripheral cholinergic nerve terminals. BoNTs are produced by
Clostridium botulinum as single chain proteins (ap. 150 kDa), which
are divided into 7 toxinotypes (A to G) according to their
immunogenic properties. The toxins are exported outside the
bacteria and are proteolytically cleaved into a heavy chain (H; ap.
100 kDa) and a light chain (L; ap. 50 kDa), which remain linked
by a disulfide bridge. The di-chain molecule constitutes the active
neurotoxin. The half C-terminal domain of the H-chain (Hc) is
involved in binding to specific receptors on target neuronal cells
and in driving the toxin entry pathway into cells, whereas the N-
terminal part permits the translocation of the L chain into the
cytosol. The L chain catalyzes a zinc-dependent proteolysis of one
or two of the three proteins of the SNARE complex, which play an
essential role in evoking neurotransmitter exocytosis. The BoNT/
A L-chain cleaves the synaptosomal associated protein SNAP25 at
the neuromuscular junction [1–4]. The highly specific binding of
BoNTs to target nerve endings involves protein and ganglioside
receptors that localize at the neuronal plasma membrane [5].
Gangliosides of GD1b and GT1b series are involved in binding and
functional entry into cells of BoNT/A and BoNT/B [6–9]. The
protein receptors on neuronal cells have been identified as
synaptotagmin I and II for both BoNT/B and BoNT/G, and
synaptic vesicle protein SV2 (isoforms A, B and C) for BoNT/A
[8,10–14], BoNT/E [15], and BoNT/F [16,17]. SV2C is the
preferred BoNT/A neuronal receptor [14], whereas BoNT/E
recognizes glycosylated SV2A and SV2B [15]. BoNT/D also uses
SV2 proteins as receptor in association with gangliosides for its
entry into neuronal cells, but binds to SV2 via a distinct
mechanism than BoNT/A and BoNT/E [18]. In addition,
SV2A and SV2B have also been evidenced to mediate the entry
of tetanus toxin (TeNT) into the central target neurons including
hippocampal and spinal cord neurons [19].
Botulism usually results from the ingestion of preformed
neurotoxin in contaminated food, or ingestion of spores or
bacteria, which under certain circumstances, may colonize the
gut and produce the neurotoxin in situ [20]. In either case, BoNT
escapes the gastro-intestinal tract to reach the target cholinergic
nerve endings, possibly through the blood and lymph circulation
[21]. Indeed, previous observations have shown that after oral
administration of BoNT in experimental animals, the toxin enters
the blood and lymph circulation. The upper small intestine was
found to be the primary site of absorption [22–25], but BoNT can
also be absorbed from the stomach [21]. Penetration of BoNT
through an epithelial cell barrier and its subsequent migration to
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intoxication. In in vitro models, BoNTs have been found to bind to
polarized epithelial cells and to undergo receptor-mediated
endocytosis and transcytosis from apical to basolateral sides
[24,26–30]. However, little is known about the precise pathway
of BoNT migration from the intestinal lumen to the target nerve
endings.
The digestive tract contains its own independent nervous
system, the enteric nervous system (ENS), which is as complex as
the central nervous system, and it is also referred as the ‘‘brain of
the gut’’. ENS controls and coordinates motility, exocrine and
endocrine secretions, and blood microcirculation of the gastroin-
testinal tract. Nerve cell bodies of ENS are clustered into small
ganglia which are organized in two major plexuses: the myenteric
plexus between the longitudinal and circular muscle layers, and
the submucosal plexus associated with the mucosal epithelium
between the circular muscles and the muscularis mucosa. Ganglia
also contain glial cells and their extensions. ENS neurons can be
classified as afferent sensory neurons, interneurons, and motor
neurons, which are connected to the central autonomic nervous
system through both sensory and motor pathways. More than 20
types of neurotransmitters have been identified in ENS, and most
enteric neurons may produce and release several of them.
However, neurotransmitter functions have not been fully identi-
fied. Secretory and motor neurons are cholinergic, these latter also
contain substance P. Myenteric neurons are connected to the
cholinergic parasympathetic neurons through nicotinic, and in
some areas, muscarinic receptors [31,32]. Vasoactive intestinal
protein (VIP) and serotonin are also major neurotransmitters in
the regulation of normal gut function and interconnection with the
central nervous system [33].
In this study, we used fluorescent Hc fragment from BoNT/A to
monitor the trafficking of the toxin into the mouse intestinal
mucosa. It has been previously shown that the Hc domain from
TeNT, which shares similar structural organization and catalytic
activity with BoNTs, is a useful tool to investigate the intracellular
trafficking of the neurotoxin [34–36]. Although, it cannot be ruled
out that a cross interplay between the BoNT domains may modify
the toxin routing driven by Hc [37], recombinant HcA has been
reported to retain the same structure than that of the receptor
binding domain of the BoNT/A holotoxin and to enter
hippocampal neurons similarly to the whole neurotoxin [16,38].
In addition, HcA has been found to bind and transcytose through
intestinal cells as well as the holotoxin [26,39], validating its use to
investigate the intestinal trafficking of the toxin.
Results
Effect of BoNT/A on muscle tension from isolated ileum
segments
In striated muscle, BoNT/A is known to inhibit ACh release
from motor nerve terminals by cleaving the synaptosomal
associated protein SNAP-25, leading to the inability of synaptic
vesicles containing ACh to undergo transmitter release [for a
review, see [3]]. In the gastrointestinal smooth muscle, BoNT/A
also impairs cholinergic transmission by inhibiting ACh release
from postganglionic cholinergic nerve endings in vitro and in vivo
[40,41]. The first aim of this study was to determine whether
BoNT/A affected smooth muscle contractility when applied intra-
luminally on isolated mouse ileum segments.
In preparations that were equilibrated in the standard
oxygenated solution for about 30 min, spontaneous contractile
responses were usually observed at a frequency rate of about 6–
10 min
21 (n=4). These spontaneous contractions had a peak
force that was variable from preparation to preparation, but
comprised between 0.5 and 1.2 g (n=4). BoNT/A reduced their
frequency after 2, 3 and 4 h of the intralumenal injection
(Figure 1A). It is worth noting that for control preparations
maintained for 4 h in the same conditions as the ones treated with
BoNT/A, not only there was no reduction of the spontaneous
contractions, but a small increase in their frequency (10% after 2
and 3 h) (Figure 1A). The contraction pattern changed also after
exposure to BoNT/A, from very regular oscillations during the
first hour to very irregular contractions after more than 2 h
(Figure 1B and 1C).
Electric field stimulation evoked contractile responses that
attained a peak force comprised between 2 and 7 mN (n=3)
under control conditions (Figure 1E), with little rundown of the
responses when stimulations were applied every 50–60 min
(Figure 1D). As shown in Figure 1D, BoNT/A reduced the
electrically-evoked contractile response in a time-dependent
manner. The time to decrease to 50% the evoked tension-time
integral response was about 110 min, and the toxin reduced to
about 90% electrically-evoked contractions within 240 min.
Although it is difficult to exclude the possibility of direct muscle
stimulation by the applied field-stimuli, several lines of evidence
indicate that this would represent no more than 10–15% of the
evoked tension-time integral response in our experimental
conditions. Most of this evidence comes from: (i) Data obtained
with BoNT/A showing that blockade of the evoked contraction
attains a maximum around 86–90% of control values, and was
never complete. The remaining tension can be suspected to be due
to direct muscle stimulation unaffected by BoNT/A. (ii) If direct
stimulation of the muscle would occur, one would expect that
tension levels would be sustained and maintained during the field
stimulation, which is not the case (Figure 1E). (iii) Spontaneous
contractions occurring during the falling phase of the evoked-
contractile response were not enhanced in amplitude, which is
consistent with the low influence of direct muscle stimulation
under the experimental conditions used. Interestingly, after
BoNT/A has blocked the evoked response by field stimulation,
Author Summary
Botulism is a severe and often fatal disease in man and
animals characterized by flaccid paralysis. Clostridium
botulinum produces a potent neurotoxin (botulinum
neurotoxin) responsible for all the symptoms of botulism.
Botulism is most often acquired by ingesting preformed
botulinum neurotoxin in contaminated food or after
intestinal colonization by C. botulinum under certain
circumstances, such as in infant botulism, and toxin
production in the intestine. The first step of the disease
consists in the passage of the botulinum neurotoxin
through the intestinal barrier, which is still poorly
understood. We investigated the trafficking of the
botulinum neurotoxin in a mouse intestinal loop model,
using fluorescent HcA (half C-terminal domain of the heavy
chain). We observed that HcA preferentially recognizes
neuroendocrine intestinal crypt cells, which likely repre-
sent the entry site of the toxin through the intestinal
barrier, then targets specific neurons, mainly cholinergic
neurons, in the submucosa, and later (90–120 min) in the
musculosa leading to local paralytic effects such as
inhibition of intestinal peristaltism. These results represent
an important advance in the understanding of the initial
steps of botulism intoxication and can be the basis for the
development of new specific countermeasures against
botulism.
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standard solution evoked a contractile response (Figure 1F). These
results suggest that under the conditions used BoNT/A is able to
exert an action on cholinergic terminals that leads to a blockade of
the contractile responses evoked by electric field stimulation, while
spontaneous myogenic contractions were reduced in frequency,
but not completely abolished. The fact that carbachol could
induce contractile activity after BoNT/A-induced blockade of
contraction evoked by electric field stimulation, strongly suggests
that the sensitivity of ACh receptors (muscarinic and nicotinic) is
not affected by the toxin (Figure 1F).
In a previous report, we have found that BoNT/A transcytosis
through intestinal cell monolayers grown on filters is mediated by
SV2C or, at least, an immunologically related protein [30]. To
address whether SV2C might be a functional receptor in the ex vivo
intestinal tract model, BoNT/A was preincubated with the
intravesicular domain segment L4 of SV2C prior to injection into
ligated intestinal loop. As shown in Figure 1A, preincubation with
Figure 1. Effect of BoNT/A on longitudinal isometric muscle contraction from mouse ileal segments. (A) Spontaneous ileal contraction
frequency as a function of time under control conditions (black colums), and after BoNT/A (10
5 LD50/ml) injection into the lumen of ligated mouse
ileal segments (white columns). BoNT/A (10
5 LD50/ml) was preincubated with GST-SV2C/L4 (20 mg/ml for 30 min at room temperature prior to being
inoculated into ligated intestinal loop. Examples of spontaneous contractions before (B), and after 4 h of BoNT/A treatment (C). Note that BoNT/A
significantly decreased, but not completely the frequency and amplitude of the spontaneous contractile activity. Data are from 3 independent
experiments. (D). Time-dependent reduction of electrically-evoked longitudinal muscle contractions after BoNT/A injection into intestinal lumen. (E)
Representative continuous control recording showing spontaneous contractions before and after single electrical field stimulation (30 Hz for 25 s,
indicated by the trace below the evoked recording). Note the changes in spontaneous contractions following the evoked one. (F) In ileal segment
treated for 4 h with BoNT/A, carbachol (20 mM) applied to the external medium (arrow) induced a sustained muscle contraction, indicating that ACh
receptors were still functional. The line segment above the tension record indicates the time of carbachol application.
doi:10.1371/journal.ppat.1002583.g001
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on spontaneous intestinal smooth muscle contractions, suggesting
a partially SV2C-dependent BoNT/A uptake through the
intestinal mucosa. However, these results do not rule out that
SV2C/L4 also passed, independently or associated with BoNT/A,
through the intestinal barrier and impaired BoNT/A uptake by
nerve terminals.
Distribution of HcA binding sites in the mouse small
intestine
We first investigated the potential binding sites for HcA in
mouse intestine mucosa and submucosa, as well as in the
musculosa. For that, cryosections of mouse small intestine, fixed
on glass slides, were incubated with fluorescent HcA and analyzed
by confocal microscopy. Since BoNT has been reported to be
preferentially absorbed from the upper small intestine [23,24],
sections from ileum were analyzed. Only a faint staining was
observed in brush border of enterocytes along intestinal villi
(Figure 2A). However, a strong HcA binding was observed on
intestinal crypt localized at the bottom of villi. Paneth cells, which
are characterized by their numerous secretory-granule content,
are spatially restricted to intestinal crypts and were used as a
marker of these regions. Staining of Paneth cells with the TRITC-
labeled lectin Urex europaeus agglutinin type 1 (UEA1) [42] did not
significantly colocalize with HcA (Figure 2B). This may indicate
that some cells from intestinal crypts, distinct from Paneth cells,
exhibit preferential binding sites for HcA. Moreover, small cells
scattered along the villi were stained with HcA (Figure 2A) and
some of them co-stained with UEA1 (Figure 2B). These UEA1
positive cells likely correspond to goblet cells [43].
It is worth noting that HcA stained neuronal cell bodies and
neuronal structures in the submucosa and musculosa. However,
only a low proportion of neuronal structures were recognized and
labeled by HcA, as revealed by immunolabeling neurofilaments
and co-staining with the fluorescent toxin fragment (Figure 2C).
Hence, the binding domain of BoNT/A potentially targets
epithelial cells in intestinal crypts, and neuronal structures of
intestinal plexuses. Note that anti-neurofilament antibodies are not
specific of the nerve endings, where BoNT/A is assumed to bind,
but recognize neuronal structures all along the neuronal cells. This
probably accounts for the irregular co-staining between HcA and
anti-neurofilament antibodies. In addition, the irregular pattern of
HcA staining might also be related to the variability in orientation
and size of the cryosections. Moreover, cryosections might
artificially expose certain antigens which are buried in intact
tissues. Thus, immunostaining pattern in cryosections has to be
considered with caution and confirmed in ex vivo experiments with
intact tissues as shown in the following figures.
Entry of HcA into mouse intestinal mucosa
To analyze HcA entry into the intestinal mucosa and
submucosa, ex vivo experiments were performed, as previously
described with the whole toxin. For this, excised small intestine
loops were washed, ligated at both extremities, and incubated in
oxygenated Krebs-Ringer solution at 37uC. Fluorescent HcA was
inoculated into the intestinal lumen, and at various time intervals,
intestinal loops were washed, fixed and processed for dissection,
and immunostaining. A competition assay between HcA-Cy3 and
native BoNT/A injected into an ileum loop and monitored by
fluorescence analysis of the intestinal mucosa, supported that
fluorescent HcA follows the same entry pathway than native
BoNT/A (Figure 3A). Fluorescent HcA entered similarly ileum,
duodenum or jejunum segments, as tested by mucosal fluorescence
analysis (Figure 3A). After 30–60 min incubation, labeled HcA
was detected inside the lumen of intestinal crypts, and in some
crypt cells, but not or with a low intensity in enterocytes or other
cells in the villi (Figure 3 B and C). HcA also labeled long cell
extensions in the submucosa, which correspond to nerve fibers or
neuronal extensions (Figure 3D; arrow head) since they were co-
stained with antibodies against neurofilaments (not shown). Longer
incubation periods (90–120 min) permitted to visualize HcA
staining of long filaments in the musculosa, (Figure 3E), which
were identified as nerve fibers from the myenteric plexus (see
below), but with a weaker intensity. This suggests a progressive
entry of HcA from the intestinal lumen through the mucosa,
preferentially through intestinal crypts, to certain neuronal cell
and extensions in the submucosa, and then in the musculosa.
HcA preferentially targets intestinal neuroendocrine
crypt cells
To identify the intestinal crypt cells targeted by HcA,
fluorescent HcA was injected into the lumen of an intestinal loop.
After an incubation of 15–30 min, the intestinal mucosa was
prepared for microscopy observation. Only few numbers (1 or 2) of
small cells from each intestinal crypt were stained with HcA
(Figure 4). Cells stained with HcA were distinct from Paneth cells,
which were easily detectable by their numerous granules (Figure 4),
and by their staining with UEA1 (not shown). Chromogranin-A
antibodies, a common marker of neuroendocrine cells in the
gastrointestinal tract [44], colocalized with HcA (Figure 4A). All
cells stained with HcA were also stained with chromogranin-A
antibodies, indicating that HcA specifically entered neuroendo-
crine cells from intestinal crypts. However, not all chromogranin-
A positive cells were stained with HcA, but only about 80%.
Serotonin-producing cells, which are abundant in the ENS, were
investigated for their colocalization with HcA. In the intestinal
crypts, all the cells stained with HcA were also immunolabeled
with serotonin antibodies (Figure 4B and C). Interestingly, HcA
accumulated in the basal pole of neuroendocrine cells, which is
wider than the apical pole exposed to the intestinal crypt lumen.
This strongly supports that HcA uses neuroendocrine cells, mostly
serotonin-producing cells, from intestinal crypts for its transport
through the intestinal mucosa.
In addition, we checked whether BoNT/A can be transcytosed
through the mouse neuroendocrine intestinal cell line STC-1 [45].
As shown in Figure 5A, the passage of biologically active BoNT/A
was monitored from apical to basolateral side of STC-1 cell
monolayers. The transcytotic passage of BoNT/A through STC-1
cells was not statistically different from that through Caco-2
enterocytes, but it was lower than through the mouse intestinal
crypt cell line m-ICcl2 as shown in Figure 5A (p,0.05) and [30]. It
is noteworthy that the passage yield through STC-1 cells was more
difficult to assess (high standard deviation values), since these cells
do not form tight junctions as epithelial cells. Since epithelial cells
such as Caco-2 and HT29 cells express at the cell surface and
secrete from apical and basolateral sides several types of proteases
[46–48], we tested whether these proteases degrade BoNT/A, thus
impairing or decreasing the transcytosis level. As shown in
Figure 5A, a 2 to 4 fold higher level of BoNT/A transcytosis
was observed in Caco-2 and m-ICcl2 cells incubated with a cocktail
of anti-proteases. However, even in the presence of anti-proteases,
BoNT/A transport was more efficient (20-fold) in m-ICcl2 than in
Caco-2 cell monolayers. Thus, the decreased BoNT/A transcy-
tosis through Caco-2 cells is not likely due to a higher protease
degradation of BoNT/A before and/or after transport. STC-1
cells possibly also secrete proteases, and a higher level of BoNT/A
transcytosis through this cell type might be expected. However,
Intestinal Entry of Botulinum Neurotoxin Type A
PLoS Pathogens | www.plospathogens.org 4 March 2012 | Volume 8 | Issue 3 | e1002583Figure 2. Binding of HcA to frozen sections of the mouse upper small intestine. (A) Sections were overlaid with Alexa488-HcA and were
counterstained with TRITC-Phalloidin. HcA staining (green) was observed in intestinal crypts, small cells in intestinal villi beneath the enterocytes, as
well as in filaments from the submucosa. (B) Counterstaining with TRITC-UEA1 (red) labeling of Paneth cells in intestinal crypts and small cells in
intestinal villi. (C) Counterstaining with anti-neurofilament (NF) antibodies and co-labelling (arrowhead) of neurofilaments with HcA in the
submucosa. (scale bars=50 mm).
doi:10.1371/journal.ppat.1002583.g002
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the results of experiments with anti-proteases were inconclusive.
As we have previously found that m-ICcl2 express SV2C or an
imunologically related protein as a putative BoNT/A receptor
[30], we investigated the presence of SV2 proteins and
chromogranin A in STC-1 and intestinal cells by Western blotting
(Figure 5B). Chromogranin A was strongly expressed in STC-1
confirming its neuroendocrine type, and to a lower extent in m-
ICcl2 and even less in Caco-2 cells, but not in Vero cells used as
negative control. Antibodies against SV2A and SV2B showed no
protein related to the expected size of SV2 (82 kDa) in intestinal
and STC-1 cells. In contrast, specific SV2C antibodies directed
against the N-terminal part or the intravesicular loop L4, which is
assumed to be the receptor binding domain of BoNT/A [11,14],
recognized a protein with the expected size in the intestinal cells
and STC-1, but not in Vero cells (Figure 5B). The specificity of
SV2 antibodies is shown in Figure S1. Next, we investigated
whether SV2C was involved in the entry of HcA into m-ICcl2 and
STC-1 cells by a competition assay between fluorescent HcA and
SV2C/L4. Cells grown on glass cover slides were exposed to HcA-
Cy3 or a combination of fluorescent Hc with a 10-fold higher
molar concentration of SV2C/L4 for 10 min at 37uC and then
processed for microscopic observation. As shown in Figure 5C,
HcA entered into m-ICcl2 and STC-1 cells, and SV2C-L4 greatly
impaired the entry of HcA into both cell types by 97 and 94%,
respectively, as determined by counting the number of fluorescent
HcA patches per mm
2 of cell area (Figure 5D), supporting the view
that SV2C participates in the entry mechanism of HcA into cells.
HcA targets specific neurons in the intestinal submucosa
After 30–60 min incubation of fluorescent HcA into an
intestinal loop lumen, HcA was detected in the intestinal
submucosa, where it stained certain neuronal structures
(Figure 6A and data not shown). Antibodies against neurofilaments
allowed visualizing a complex and abundant network of neuronal
cell bodies and neuronal extensions in the submucosal plexus
immediately underneath intestinal villi and crypts. Only some of
these neuronal structures were stained with HcA (Figure 6A).
BoNTs are well known to interact with cholinergic neurons and
to specifically block spontaneous and evoked quantal acetylcholine
release [4,49]. However, it has been shown that BoNT/A and
BoNT/E are also able to enter other neuronal cell types such as
glutamatergic and gamma-aminobutyric acid (GABA)-ergic neu-
rons, as well as astrocytes [50,51]. Since ENS contains a large
variety of neuronal cell types, we investigated the most
representative types as putative targets of HcA in the mouse small
intestine.
Cholinergic neurons were monitored by immunostaining with
antibodies for choline acetyltransferase (ChAT). ChAT-immunore-
active neurons are abundant (about 55%) in the submucosal plexus,
where they are involved in various gut functions including the
controlofevoked anionsecretionbythe jejunal and ilealepithelium,
and they also interact with Peyer’s patch follicles [52,53]. Most of
ChAT-immunoreactive nerve terminals from the intestinal submu-
cosa were labeled with fluorescent HcA (Figure 6B and G).
Vasoactive intestinal peptide (VIP)-immunoreactive neurons are
known to be located in jejunum and ileum submucosal plexus, as
well as in other organs. VIP modulates several basic functions
including blood flow, smooth muscle relaxation, and exocrine
secretion [54]. VIP-immunoreactive neurons are estimated to
represent about 45% of neurons from the submucosal plexus
[53,55]. Numerous cells were immunostained with anti-VIP
antibodies in mouse intestinal submucosa, but a colocalization
between VIP immunoreactivity and HcA staining was only
observed in a few of them (less than 3%) (Figure 6C and G).
Note that some of the filaments and cell bodies stained with anti-
VIP antibodies did not colocalize with neurofilament staining, and
may probably represent glial structures.
Glutamatergic neurons, which are the major neurons from the
central nervous system involved in excitatory responses, are also
present in ENS. Glutamate receptors have been detected in enteric
neurons and glutamatergic enteric neurons where they have been
found to mediate excitatory synaptic transmission, whereas only a
subset of them are involved in sensory responses [56]. In mouse
intestinal submucosa, only a low number of glutamatergic neurons
(less than 1%), as evidenced by anti-glutamate antibodies,
colocalized with HcA (Figure 6D and G).
Serotonin is also an important neurotransmitter in ENS, where
it is involved in the control of motility, secretion and sensory
functions. Serotonin is produced by 2 to 20% of all enteric neurons
[33]. In our analysis only a few neuronal cell extensions were
stained with anti-serotonin antibodies in the submucosal plexus,
and some of them were also labeled with HcA, as shown in
Figure 6E.
Glial cells were neither immunostained with anti-neurofilament
antibodies nor with HcA, but exhibited a clear immunolabelling
with GFAP antibodies (data not shown). These results support the
view that HcA binding is mostly specific of nerve endings in the
intestinal submucosa.
HcA preferentially targets ChAT-immunoreactive neurons
in mouse intestine musculosa
Also, we investigated the intestine musculosa, which is the
predicted target tissue of BoNT/A for its inhibitory activity on
intestinal motility. No significant HcA staining was observed in the
musculosa 30 or 60 min after incubation with the fluorescent
probe in the intestinal loop, and only a few cell bodies or
extensions were stained after a longer incubation period (90–
120 min) in our experimental conditions. Cell extensions stained
with HcA colocalized with neurofilament staining (Figure 7).
However, only some of the nerve endings were labeled with HcA.
Almost all cell bodies labeled with HcA exhibited ChAT-
immunoreactivity. Similar results of colocalization with ChAT-
immunoreactive neurons were obtained using full length BoNT/A
injected into the intestinal loop lumen and detected with anti-HcA
antibodies (Figure S2). This is consistent with the fact that a large
majority of neurons in the myenteric plexus are immunoreactive
for ChAT, albeit many of them produce additional neurotrans-
mitters [55]. No significant colocalization was observed between
Figure 3. Visualization of HcA in the mouse intestine following inoculation into the intestinal lumen. (A) HcA-Cy3 (0.5 mg) was injected
into ligated ileum, duodenum, or jejunum loop. After 30 min of incubation, the samples were fixed and the mucosal fluorescence was measured as
the number of HcA-positive cells per crypt. The number of labeled cells was similar between the three intestinal segments, but significantly lower (*)
in the competition assay with BoNT/A (2.5 mg) in an ileal loop (Student’s t test). (B) Detection of HcA (green) in the intestinal crypts and in some
submucosa areas. No or only weak labeling is observed in the intestinal villi. (C) Visualization of HcA in intestinal crypt lumen (arrow-head) and inside
some intestinal crypt cells (arrow), and (D) on filaments in the submucosa (black arrow head) after 30 min incubation. (E) HcA labeling of filaments
(corresponding to neurofilaments, see Figure 7) in the musculosa after 90 min incubation. (scale bars=20 mm).
doi:10.1371/journal.ppat.1002583.g003
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the myenteric plexus (data not shown).
BoNT/A receptor SV2 is expressed in certain intestinal
neurons and glial cells
The protein receptor of BoNT/A on neuronal cells has been
identified as SV2. Among the three SV2 isoforms, SV2C shows
the highest affinity to BoNT/A in vitro, whereas BoNT/A binds to
SV2A and SV2B with a lower strength [11,14,57]. SV2A is
present in almost all neurons whatever their neurotransmitter type
is, while SV2B shows a more restricted distribution. SV2C is
reported to be present in a subset of neurons [58]. However, SV2
proteins are expressed not only in neuronal cells, but also in other
cell types such as neuroendocrine cells, in particular in the
gastrointestinal tract [59]. We investigated the distribution of SV2
proteins in mouse intestinal mucosa with our in toto tissue model.
Numerous cell extensions in the submucosal plexus were stained
with anti-SV2C antibodies (Figure 6F), whereas no specific
staining was observed with anti-SV2B antibodies, and only a
diffuse staining in certain crypt cells and cell extensions in the
submucosa was evidenced with anti-SV2A antibodies (data not
shown). The mouse intestinal crypt cell line m-ICcl2 was found to
express SV2C at a higher level than in enterocyte-type cell lines
(Figure 5B and [30]). However, in our ex vivo conditions intestinal
crypt cells were not, or only weakly immunoreactive with anti
SV2C antibodies. This does not preclude that a subset of crypt
cells express a significant level of SV2C that was not detected in
our conditions. Most of SV2C-immunoreative filaments in the
submucosa, were also labeled with anti-neurofilament antibodies,
indicating that SV2C is widely distributed in neuronal cells and
neuronal extensions from the small intestine. However, HcA signal
was observed in only some neuronal endings bearing SV2C, but
not along the neuronal extensions stained with anti-SV2C
antibodies (Figure 6F). Only a low proportion of SV2C-
immunoreactive cells were labeled with HcA (Figure 6G). It is
worth noting that a distinct network of thin filaments around small
blood vessels was stained with anti-SV2C, and only weakly with
anti-neurofilament antibodies. No specific binding of HcA was
observed on these structures (Figure S3A and B). In the intestinal
submucosa and musculosa, large cells with wide cellular bodies
and short extensions were stained with anti-SV2C antibodies, but
not with anti-neurofilament antibodies. Co-labelling with anti-
GFAP indicated that they were glial cells (Figure S3C). However,
HcA, as reported above, was not found to label glial cells.
Discussion
The standard scheme of botulism intoxication includes BoNT
transit through the digestive tract, passage across the intestinal
epithelial barrier and subsequent delivery to the blood circulation
and dissemination to the target motor nerve endings. Indeed,
BoNT has been found to be absorbed preferentially from the
upper small intestine, but also from the stomach in experimental
rodents, and to be delivered in the blood and lymph circulation
[21,23,24,60]. The aim of this study was to identify the entry
pathway and target cells of BoNT/A in the mouse intestinal wall.
For that, we checked the activity of BoNT/A in mouse intestine
following intralumenal administration and we used the fluorescent
Hc domain, which is the functional binding domain of BoNT, to
monitor the trafficking of BoNT/A.
First, we tested whether BoNT/A injected into intestinal lumen
was able to enter intestinal mucosa and to induce local effects on
the intestine. In vitro studies have already shown that BoNT/A
reduces cholinergic transmission in gastrointestinal smooth
muscles as well as pylori and Oddi sphincter muscles by inhibiting
ACh release [40,41,61–63]. In our experimental conditions,
BoNT/A passed through the epithelial intestinal barrier and by
diffusion through the extracellular space, locally targeted intestinal
neurons independently of the blood circulation. BoNT/A reduced
the frequency of spontaneous contractions of small intestine and
inhibited the contractile response evoked by electric field
stimulation within 2–4 h after intralumenal administration. Since
carbachol was still able to stimulate muscle contraction after
BoNT/A treatment, this supports a toxin-dependent inhibition of
ACh release. To the best of our knowledge, this is the first report
demonstrating a local intestinal effect of botulism after intralume-
nal administration of purified BoNT/A. Constipation is often
(about 70%), but not always, associated with food-borne botulism
and its participation to the progression of the disease is unknown
[64,65]. However, constipation is a major and early symptom of
botulism resulting from an intestinal colonization by C. botulinum
such as during infant botulism [66,67]. This digestive symptom
might result from a local effect of BoNT after crossing the
intestinal barrier instead of toxin dissemination through the
general circulation. BoNT locally synthesized in the intestine is
possibly absorbed in a higher local concentration able to induce an
intestinal muscle paralysis, than toxin orally ingested which
disseminates more broadly through the digestive tract. Interest-
ingly, BoNT/A-dependent inhibition of evoked smooth muscle
contraction was significantly prevented by preincubation with the
intravesicular domain of SV2C. This indicates that a protein
related to SV2C/L4 might impair the BoNT/A passage through
the intestinal barrier and/or toxin uptake by the underlying nerve
terminals. We have previously found that SV2C, or a related
protein, is part of BoNT/A receptor mediating toxin transcytosis
through cultured intestinal cell monolayers [68]. In addition,
SV2C/L4, which is expressed by intestinal and neuroendocrine
STC-1 cells (Figure 5B), significantly prevented HcA entry into the
intestinal crypt m-ICcl2 and STC-1 cells (Figure 5C, D). Taken
together, these data suggest that SV2C, or a related protein,
facilitates BoNT/A uptake through the mouse intestinal barrier.
BoNT/A trafficking in mouse intestinal wall was investigated
with fluorescent HcA as already used [38]. First, we investigated
the potential binding sites of HcA by using mouse small intestine
cryosections overlaid with fluorescent probes. Thereby, HcA was
found to bind only to certain cell types of the intestinal mucosa,
Figure 4. Visualization of HcA in neuroendocrine cells from mouse intestinal crypts. Fluorescent HcA (0.5 mg) was injected into the lumen
of a mouse ileum (A, B) or duodenum (C) loop, and after 30 min incubation the intestinal loop was washed and prepared for immunostaining with
chromogranin A or serotonin antibodies. (A) Two cells stained with chromogranine A antibodies in an intestinal crypt (dotted circle) were co-labeled
with HcA (green). Magnification of one cell (square) shows a uniform punctuate distribution of chromogranin A staining, whereas HcA was
preferentially localized at the basal pole. Phase contrast shows that the chromogranin A-immunoreactive cell contained no large granules, in contrast
to Paneth cell (black cross). (B) Co-labeling of a cell from an intestinal crypt (dotted circle) with HcA (green) and serotonin antibodies (red).
Magnification of the cell (square) shows a basal distribution of both HcA and serotonin. Note that a cell extension was also labeled with serotonin
antibodies but not by HcA (arrowhead), and that the serotonin-immunoreactive cell contained no large granules as in Paneth cells (black cross) (scale
bars=10 mm). (C) Co-labeling of HcA (red) with serotonin (green) in a duodenum crypt cell. Neurofilament staining (blue) was observed at the crypt
periphery.
doi:10.1371/journal.ppat.1002583.g004
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only a weak staining of the brush border. In contrast, it was
reported that the botulinum complexes type A or type C (BoNT
and associated non-toxin proteins, ANTPs), strongly bind to the
epithelia cell surface and goblet cells of guinea pig small intestine.
Moreover, this binding was shown to be mediated by the
hemagglutinins HA1 and HA3b, which interact with distinct
gangliosides and/or glycoproteins [24,29,60,69] from those
recognized by the neurotoxin alone [11,14]. This certainly
accounts for the differential binding between progenitor toxin
and BoNT to intestinal epithelial cells.
The functions of ANTPs are still controversial. Ancillary
proteins probably participate in BoNT protection from degrada-
tion inside the digestive tract in a dose-dependent manner,
particularly in the stomach [21]. In addition, it is assumed that
HAs are involved in the internalization of progenitor type C toxin
into intestinal cells and subsequently in the small intestine
[24,29,70], and that they disrupt the intestinal epithelial barrier
facilitating toxin absorption via the paracellular route [71–74].
However, since BoNT/A absorption from mouse stomach or small
intestine was found to occur independently of the presence of
ANTPs, HAs might have not an essential role but an additional
facilitating effect on BoNT/A passage through the intestinal
barrier. At pH around neutrality, as found in the intestine, BoNT
dissociates from ANTPs [75], and thus might be absorbed through
the epithelial intestinal barrier independently of ancillary proteins.
In our model of ligated mouse intestinal loops and recording of
muscle contraction, BoNT/A entered the intestinal mucosa in the
absence of ANTPs supporting that ANTPs are not absolutely
required in the intestinal uptake of BoNT/A.
The main finding of the ex vivo intestinal loop experiments was
that fluorescent HcA preferentially recognized certain crypt cells.
Intestinal crypts contain stem cells which proliferate and
differentiate in four main cell types including enterocytes, mucus,
endocrine, and Paneth cells, which are the most abundant cell type
at the bottom of intestinal crypts [76]. HcA labeling was observed
in chromogranin- and serotonin-immunoreactive cells, but not in
Paneth cells. It is noteworthy that HcA was detected in only some,
but not all, chromogranin-immunreactive cells. This strongly
suggests that HcA specifically binds to a subset of neuroendocrine
cells from intestinal crypts, which possibly represent the preferen-
tial site of toxin uptake.
BoNT/A has been found to pass through intestinal cell
monolayers grown on filter by a transcytotic mechanism [26,27].
We have previously reported that the passage rate of biologically
active BoNT/A was higher (about 10-fold more) through the
mouse crypt cell line m-ICcl2 than through the colonic enterocyte
lines Caco-2 and T84 [30]. Here, we found that the neuroendo-
crine intestinal cell line STC-1 also permits a transcytotic passage
of BoNT/A not statistically different from that through Caco-2
cells and to a lower extent than in m-ICcl2 cells. This further
supports that a subset of intestinal crypt cells constitute a
preferential entry site of BoNT/A within the intestinal mucosa.
However, STC-1 cells, which derive from an intestinal endocrine
tumor, secrete several hormones and neuropeptides, but not
serotonin [45]. Thereby, STC1 cells are not the most represen-
tative cells of the serotonin-reactive cells co-labeled with HcA,
which have been identified in intestinal loop tests. To the best of
our knowledge, no intestinal serotonin-secreting endocrine cell line
is known at present. m-ICcl2 cells, which have been isolated from
fetal mouse intestine, express various markers of intestinal cells and
thus are a totipotent intestinal crypt cell line in a less differentiated
state than the tumor cell line STC-1 [77]. m-ICcl2 cells show a
neuroendocrine-like phenotype since they synthesize chromogra-
nin A albeit to a lower extent than STC-1, but more significantly
than Caco-2 cells (Figure 5B). In addition, m-ICcl2 cells retain
transport pathways similar to those of native crypt cells. Indeed, in
contrast to colonocytes such as Caco-2 and HT29 cells, m-ICcl2
cells express polymeric Ig receptors (pIgRs), which mediate the
transepithelial transport of polymeric IgA and IgM [77]. It is
noteworthy that only a low number of cells (1 to 2) from each
intestinal crypt were labeled by HcA and are likely susceptible to
transport the toxin through the intestinal barrier. This might
account for the low rate of BoNT absorption from the digestive
tract to the general circulation. Indeed, the transport rate of
BoNT/B from rat duodenum to the lymphatic circulation has
been estimated from 0.01 to 0.1% [22]. In addition, chromo-
granin-immunoreactive cells are distributed throughout the
gastrointestinal tract, but are more predominant in the pylorus
and duodenum [78]. This might support the observation that the
upper small intestine is the preferential site of BoNT absorption
[22–25].
Using the intestinal loop model, we found that neuronal cells in
the submucosa and more lately in the musculosa were stained with
HcA. However, not all the neuronal cells were recognized by HcA
as tested by co-labeling with antibodies against neurofilament,
indicating that HcA targeted specific neurons in the intestine.
About half of neurons in the submucosa are ChAT-immunore-
active, and most of them produce other neurotransmitter types
[53,55]. As previously found [79], HcA stained most of the
cholinergic neurons (more than 90%) of the submucosa. However,
in contrast to previous findings [79], BoNT/A recognized other
neuronal cells in the intestinal mucosa, albeit to a lower extent.
Indeed, a low proportion of VIP-immunoreactive neurons, which
are also largely present in the submucosa (about 45%) [53] as well
as a low proportion of glutamatergic and serotoninergic neurons
were targeted by HcA. It is noteworthy that the BoNT/A
receptor, assigned to ganglioside GD1b/GT1b and SV2 protein
[6,7,10,14], is part of a synaptic vesicle complex, which contains
additional membrane proteins including vesicular glutamate
transporters (cGLY-1 and vGLUT-2) [80], supporting that
BoNT/A may target glutamatergic neurons. BoNTs are known
to block the release of ACh, but also that of other neurotransmit-
ters and neuropeptides the effects of which are still poorly known
Figure 5. Transcytosis of BoNT/A through intestinal and neuroendocrine cell monolayers, and SV2C-dependent entry of HcA into
cells. (A) Transcytosis of BoNT/A trough the intestinal neuroendocrine cell line STC-1, m-ICcl2, and Caco-2 cells. Cells were grown on filters (Transwell)
until confluence. Integrity of cell monolayers was confirmed by ZO-1 labeling and non-permeability to FITC-labeled dextran (4300 Da). BoNT/A was
added to the upper chamber and 60 min after incubation at 37uC, the toxin was assayed in the lower chamber by mouse bioassay. The results were
expressed as the mean percentage (n=9) of transcytosed BoNT/A corresponding to the ratio of mouse lethal dose 50 between the lower and upper
well (inoculation titer). BoNT/A transport was significantly higher (*) in m-ICcl2 and in cells treated with anti-proteases (Student’s t test). (B)
Immunoblotting of cell lysates separated by SDS-PAGE with anti-chromograninA, anti-SV2A, anti-SV2B, anti-SV2C, and anti SV2C-L4 antibodies. (C)m -
ICcl2 and STC-1 grown on glass cover slips were exposed to HcA-Cy3, alone or in combination with a 10-fold more molar concentration of SV2C/L4-
GST for 10 min at 37uC. SV2C/L4 impaired HcA uptake in both m-ICcl2 and STC-1 cells. (D) The number of HcA fluorescent patches per mm
2 in m-ICcl2
and STC-1 cells were reduced by 97% and 94% respectively (p,0.0001) by incubation with SV2C/L4. Each column represents the mean 6 SEM
(n=250).
doi:10.1371/journal.ppat.1002583.g005
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ChAT neurons in the intestine may contribute to the local effects
of the toxin.
In the myenteric plexus, HcA stained essentially cholinergic
neurons, which are the predominant neuronal cells in this tissue
(about 80%) [53]. But, only a part of ChAT-immunoreactive
neurons were labeled with HcA. This might be due either to a low
number of Hc molecules reaching the myenteric plexus, or to the
fact that HcA recognized only a subset of ChAT-reactive neurons,
which remains to be determined. Targeting of cholinergic neurons
of the myenteric plexus by HcA is consistent with constipation
which frequently occurs during botulism, and with the BoNT/A-
dependent inhibition of evoked intestinal contractions in the ex vivo
experiments.
SV2C, the protein receptor with the highest affinity to BoNT/A
[10,14], was the main isoform detected in the mouse intestine,
whereas no, or a weak staining was obtained with anti-SV2B or -
SV2A antibodies. Immunostaining with anti-SV2C antibodies was
observed in cells with thin arborescent extensions, which were also
labeled withanti-neurofilament antibodies.However,SV2Cstaining
didnotmatchallthecellslabeledwithanti-neurofilamentantibodies,
indicating a SV2C distribution in a broader range of cell types than
neuronal cells in the intestinal mucosa. HcA did not bind all along
the neuronal extensions or cell structures which are recognized by
anti-SV2C antibodies, but only in discrete zones. One possibility is
that HcA staining was too weak to be visualized. Alternatively, the
BoNT/A high-affinity receptors, which consist of a ganglioside part
and a protein part such as SV2C [11,14–17], are distributed in only
some restricted areas on the neuronal cell surface. This is supported
by the observed colocalization between HcA and SV2C, which is
restricted to only some cell areas (Figure 6F). Moreover, SV2, which
is an integral protein of the synaptic vesicle membrane, has to be
exposed to the extracellular compartment to be accessible to BoNT/
A, as during synaptic vesicle fusion with the presynaptic membrane.
Another type of thin cell extensions stained with anti-SV2C
antibodies, formed a dense network all around microvessels (Figure
Figure 6. Neuronal cell types recognized by HcA in the intestinal submucosa after its inoculation into the intestinal lumen (30 min
incubation). (A) Cells and neuronal structures labeled with HcA (green) were immunoreactive to anti-neurofilament (NF, red), indicating that HcA
reached neuronal structures in the submucosa. Note that only few neurons and neuronal extensions were labeled with HcA (B) Co-staining with ChAT
shows that some but not all ChAT-immunoreactive neurons were labeled with HcA. (C) Co-staining with anti-VIP antibodies showing no
colocalisation with HcA. (D) Co-staining with anti-glutamate. Note that only a few neurons stained with anti-glutamate antibodies colocalized with
HcA (scale bar=20 mm). (E) Co-staining with anti-serotonin antibodies. Only few neurons stained with anti-serotonin antibodies colocalized with HcA.
Note in the phase contrast in (E) that serotonin labeling was observed in some crypt intestinal cells and a few nerve endings in the submucosa. (F)
Anti-SV2C and anti-neurofilament antibodies stained neurons and thin neuronal extensions in the submucosa. HcA labeled only certain nerve
endings (arrows). Note that some SV2C-immunoreactive large cells with thicker extensions were neither stained with anti-neurofilament antibodies
nor with HcA. (G) Quantification of colocalization between HcA and neurotransmitter markers in mouse intestinal submucosa. Results are expressed
as colocalization index for which 1 represent 100% of colocalization between HcA and a neuronal marker. Colocalization index represents the ratio of
the number of HcA positive terminal endings colocalized with one neurotransmitter marker to the total number of terminal endings labeled with
HcA. Columns represent means 6 SD accounting for at least 50 cells in three different experiments.
doi:10.1371/journal.ppat.1002583.g006
Figure 7. HcA labeled cholinergic neurons in the musculosa after 90 min exposure in the intestinal lumen. Co-staining with anti-ChAT
and/or anti-neurofilament antibodies. Note that HcA preferentially stained neuronal cell extensions and to a lower extent cell bodies. (scale
bar=20 mm).
doi:10.1371/journal.ppat.1002583.g007
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anti-neurofilament antibodies, are probably involved in vessel
innervation [87], but were not observed to be targeted by HcA
under our experimental conditions. In addition, glial cells identified
by GFAP immunofluorescence were also stained with anti-SV2C
antibodies but not with HcA (Figure S3C). Thereby, SV2C seems to
have a broad distribution and to form BoNT/A high-affinity
receptor only when associated with gangliosides in certain neuronal
membrane domains.
When passed across the intestinal barrier, BoNT is delivered to
the connective tissue of the submucosa, where the toxin can have
access to microvessel endothelial cells. BoNT passage into the blood
and lymph circulation, supposes a transcytotic transport of the toxin
through the endothelial cell barrier of vessels. In ligated intestinal
loop experiments, no staining of endothelial cells forming small
vessels or microvessel structure was observed in the submucosa and
musculosa. Under natural conditions, BoNT binding to endothelial
cells is possibly low and/or transient permitting the passage of the
toxin into the vessel lumen. In our experimental conditions, the
blood circulationwas interrupted, thus preventing HcA passage into
vessels. But, the diffusion through the matrix of connective tissue
can mediate the toxin trafficking until the target cells in the
submucosa and musculosa. Indeed, HcA staining of neuronal cells
in the submucosa after 30–60 min incubation of the probe into the
intestinal lumen and later (60–120 min) in the musculosa, as well as
the decrease in fluorescence intensity of HcA from the mucosa to
musculosalikelyreflectsthe progressivediffusionoftherecombinant
protein in the tissue extracellular matrix. It cannot be ruled out that
a shorter time period may be required in natural conditions for the
passage of low amounts of HcA across the intestinal epithelial cell
barrier and subsequent targeting to neuronal cells. Alternatively,
another mode of HcA transport might be involved. Indeed, like
TeNT, which undergoes a retrograde transport intomotor neurons,
a transcytotic mechanism might also be supported by neuronal cells
from the ENS to disseminate BoNT/A to target neuronal cells both
locallyandevenatdistance from the intestine.Onepossibilityis that
BoNT/A uses non-cholinergic neurons such as those identified with
fluorescent HcA to be transported to other target neurons. Indeed,
neurons from ENS are highly interconnected between them and
withneurons of the centralnervoussystem[31,32]. Moreover,it has
been recently found that BoNT/A can use a retrograde transport
and transcytosis to migrate from peripheral neurons to central
circuits [88,89]. This opens novel ways of investigation to unravel
the mechanism of BoNT transport from the intestinal barrier to
target motoneurons, which is still poorly known.
In conclusion, in this work we have shown that BoNT/A enters
the intestinal mucosa, possibly via an uptake process involving
SV2C or a related protein, and impairs spontaneous and
electrically-evoked muscle contractions. Following intralumenal
administration, HcA preferentially recognized a subset of
neuroendocrine crypt cells in the mouse upper small intestine,
which likely represents the main pathway for toxin entry and
passage across the epithelial cell barrier. HcA diffused progres-
sively within the submucosa, and later reached the musculosa,
where it targeted specifically some cholinergic neurons and to a
lower extent glutamatergic and serotoninergic neurons. The
implication of these non-cholinergic neurons in the botulinum
intoxication process remains to be determined.
Materials and Methods
Ethic statements
All experiments were performed in accordance with French and
European Community guidelines for laboratory animal handling.
The protocols of experiments were approved by the Pasteur
Institute (Agreement of laboratory animal use nu 75-279).
Reagents
The primary antibodies used recognized neurofilament (Sigma;
mouse, 1:500 dilution), Glial Fibrillary Acidic Protein (GFAP)
(Sigma; rabbit, 1:200 dilution), Choline Acetyltransferase (ChAT)
(Chemicon International, Temecula, CA, USA; goat, 1:100
dilution), VIP (Abcam; rabbit, diluted 1:200), Serotonin (Sigma;
rabbit, diluted 1:100; and Abcam ; goat, 1/200 dilution),
Glutamate (Chemicon; rabbit, diluted 1:200), SV2A, SV2B
(Synaptic systems; rabbit, diluted 1:200), SV2C (Santa Cruz; goat,
diluted 1:200), chromogranin A (Abcam; rabbit, diluted 1:200).
For Western blotting rabbit anti-SV2C (Abcam 33892) and rabbit
anti-SV2C intravesicular domain were used. SV2C/L4 domain
(amino acid 454 to 579) was produced as a GST-fusion protein
[30] and was used to immunize rabbits. Specific antibodies against
SV2C/L4 were purified by immunoaffinity with SV2C/L4
produced as a histidine-tagged protein in pET28 vector (Novagen)
and immobilized on cyanogen bromide activated Sepharose-4B
(GE Healthcare).
The secondary antibodies used were: Cy5 coupled donkey anti-
mouse IgG (US Biological), Cy3 coupled donkey anti-goat IgG
(US Biological), Alexa488 donkey coupled anti-goat IgG (Invitro-
gen), Alexa488 coupled anti-rabbit IgG (Invitrogen). 49-69-
Diamidino-2-phenylindole (DAPI, SIGMA) was incubated with
secondary antibodies to stain cell nuclei.
Animals
Adult male IOPS mice (20–25 g body weight) purchased from
Charles River Laboratories (L’Arbresle, France) were anesthetized
by inhalation with Isoflurane (AErrane, Baxter S.A., Lessines,
Belgium), and euthanized by dislocation of the cervical vertebrae,
as specified by the CNRS Animal Ethics User’s Committee.
Protein production
BoNT/A was produced and purified as previously described [90].
Recombinant His-tag Hc fragment of BoNT/A was produced
and purified from pET28b vector containing DNA encoding for
HcA cloned into BamHI and SalI sites, as previously described
[91]. A recombinant derivative plasmid encoding HcA with a N-
terminal tag containing 4 cystein residues, as described for TeNT-




CAAGCCTCTCGTGCTGC TGCCTCTGCCA-39) into NdeI
and BamHI sites of pET28b vector. HcA with 4 Cys tag was then
labeled with either maleimide Alexa 488 reagent (InVitrogen,
Cergy-Pontoise, France) or maleimide Cy3 (Amersham, Les Ulis,
France) according to the manufacturer’s recommendations.
cDNA coding the intraluminal SV2C fragment L4 (amino acid
454 to 579) was PCR-amplified as previously described [68] and
cloned into pGEX-2T. The fusion protein, GST-SV2C/L4, was
produced in E. coli BL21 and purified on glutathione agarose
matrix (SIGMA) equilibrated with 50 mM Tris-HCl, 300 mM
NaCl, pH 7.5 and eluted with 40 mM reduced glutathione in the
same buffer. Purified fusion protein was then dialyzed against
phosphate balanced solution (PBS) before use.
Tension recordings on isolated mouse ileum segments
The mouse ileum was removed and placed in an oxygenated
standard Krebs-Ringer solution composed of 154 mM NaCl,
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5 mM HEPES (pH 7.4). An ileum segment of about 2 cm length
was extensively washed to flush out the intestinal content, and
mounted in a silicone-lined chamber (4 ml volume), bathed in the
standard medium. For tension measurements, one of the ends of
the ileum segment was tied with silk thread, via an adjustable
stainless-steel hook, to an FT03 isometric transducer (Grass
Instruments, AstroMed, W. Warwick, RI, USA), and the other
end was ligatured and pinned onto the silicone-coated bath via
stainless-steel micro pins. BoNT/A (5 mg/ml) diluted in the Krebs-
Ringer solution was injected into the ileum segment, between the
two ligatures, with a micro syringe. Electric field stimulation was
performed with an electrode assembly, placed along and on both
sides of the length of the ileum segment, and connected to S-48
Grass stimulator. Preparations were usually stimulated with pulses
of 0.15 ms duration at 30 Hz for 15 or 25 s, every hour. The
resting tension was adjusted for each preparation investigated with
a mobile micrometer stage (to allow incremental adjustments of
ileum length) in order to obtain maximal spontaneous or evoked
contractile responses, and was monitored during the whole
duration of the experiment. Carbachol (Sigma, 20 mM) was added
to the bath solution of ileal segment exposed to BoNT/A for 3–
4 hours to check that ACh receptors were not affected by
intoxication. Tension signals from the isometric transducer were
amplified, collected, and digitized with the aid of a computer
equipped with a DT2821 analogue to digital interface board (Data
Translation, Marlboro, USA) and expressed in g or N. Data
acquisition and analysis were performed with a program kindly
provided by Dr. John Dempster (University of Strathclyde,
Scotland). All experiments were performed at 2260.5uC.
Ex-vivo experiments with mouse ligated ileal loops
Segments of mouse ileum (2 cm length) were removed and
immersed in oxygenated Krebs-Ringer solution. After extensive wash
to flush out the luminal contents, segments were ligated on both
extremities and injected with a micro syringe with fluorescent HcA
(0.5 mg) diluted in 150 ml of Krebs-Ringer solution (5.5 10
28 M). The
injection site was isolated with another ligature and ileal segments were
incubated in oxygenated Krebs-Ringer solution for different times (30
to 120 min) before washing. Tissues were cut along the mesenteric
border and pinned out with the mucosal surface facing down in a
silicone-lined Petri dish. After fixation with 4% paraformaldehyde
(PFA; 1 h, 22uC), tissues were washed in phosphate buffer saline (PBS)
and autofluorescence quenched with 50 mM NH4Cl (30 min, 22uC).
Microdissection and indirect immunofluorescence of
dissected ileal loops
Specimens were dissected by carefully separating the mucosa and
submucosa from the muscle layers under a microscope. Whole-
mount preparations of the myenteric and submucosal plexuses of
the ileum were permeabilized and blocked with PBS/bovine serum
albumin (BSA) 2%/Donkey Serum 10%/Triton 2% for 1 h at
room temperature (RT) and incubated with primary antibody for
16 h at RT. After 3 washes of 10 min in PBS, tissue sections were
incubated for 4 h at RT with the appropriate secondary antibodies
diluted 1:500 in PBS/BSA 2%/Triton 2%. After being washed in
PBS (3610 min), tissues were mounted in Mowiol (Polysciences
Europe, Eppelheim, Germany) and analyzed using a Zeiss confocal
laser scanning microscope and a663 oil immersion objective (N.A.
1.4). For quantitative analysis of co-localization of HcA with other
markers, images of 5126512 pixels were taken from series of optical
sections of 0.8 mm thickness. The colocalisation was analyzed with
the Zeiss LSM Image Browser software, on 100 HcA-immunore-
active varicosities for each marker using the merged image from the
different experiments. For analysis of BoNT/A internalization into
intestinal cells, total fluorescence intensity was quantified in
serotonin-positive cells in at least 40 optical fields taken from three
independent experiments. Data are presented as the mean 6 SD.
Small intestine cryosections
Segments of the ileum were removed and immersed in
oxygenated Krebs-Ringer solution. After extensive wash to flush
out the luminal contents, the tissues were embedded in OCT
embedding medium (Tissue-Tek, Miles Laboratories, Naperille, IL,
USA), and stored at 280uC. Sections (5 mm) were cut with a
cryostat-microtome and thaw, mounted onto SuperFrost glass slides
(Fisher Scientific, Illkirch, France). For HcA binding experiments,
sections were removed from the freezer and incubated for 30 min
with 10 mg/ml Alexa- or Cy3-labeled HcA in PBS/BSA (1%). After
3 washes in PBS, tissue sections were fixed with 4% PFA for 20 min
at RT (22uC), rinsed in PBS and autofluorescence was quenched
with 50 mM NH4Cl (15 min, 22uC). After permeabilization with
1% triton X-100 in PBS for 10 min, tissues were stained with
TRITC-phalloidin (Sigma, 0.4 mg/ml), TRITC-Urex europaeus
agglutinin type 1 (UEA1, 1 mg/ml), immunostained with anti-
neurofilament 200 (Sigma; mouse, diluted 1:500) and Cy3 coupled
goat anti-mouse IgG (Sigma, diluted 1:250). After 3 washes in PBS,
sections were mounted in Mowiol and observed with a Zeiss
confocal laser scanning microscope and a 625 objective. For
quantitative analysis of co-localization of HcA with markers, images
of 5126512 pixels were taken from serial optical sections of 1 mm
thickness. Data are presented as the mean 6 SD.
BoNT/A transcytosis and immunofluorescence
experiments
The mouse neuroendocrine intestinal cell line STC-1 [45], m-
ICcl2 [77] and Caco-2 (human colon) cells were grown on filter
(Transwell, Corning) in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen) supplemented with 10% fetal calf serum
(FCS, Invitrogen) until confluence. Integrity of tight junctions was
confirmed by ZO-1 labeling and non-permeability to FITC-
labeled dextran (4300Da, Sigma-Aldrich) (data not shown).
BoNT/A as prepared previously [30] was added to the apical
chamber. After 60 min incubation at 37uC, medium from the
basal chamber was collected and BoNT/A was assayed by the
mouse bioassay as previously described [30]. In the experiments
with anti-proteases, culture medium in the apical and basolateral
chambers was replaced with Dulbecco’s medium containing 1%
bovine serum albumin (BSA) and 16anti-protease coktail without
EDTA (Calbiochem) 30 min prior addition of BoNT/A into the
apical compartment. BoNT/A transcytosis was monitored in
basolateral medium samples after 60 and 120 min incubation at
37uC by a biological assay as previously described [30].
m-ICcl2 and STC-1 cells grown on glass coverslips (coated with
poly-ornithine, Invritrogen, for STC-1 cells) were exposed to HcA-
Cy3 (2.5 mg/ml), alone or in combination with a 10-fold more
molar concentration of SV2C/L4-GST for 10 min at 37uC. Cells
were washed twice with PBS, fixed with 4% PFA and mounted in
Mowiol. The number of HcA fluorescent patches per mm
2 was
evaluated in m-ICcl2 and STC-1 cells by counting in images of
5126512 pixels (10 optical fields), taken from serial optical sections
of 1 mm thickness from 3 experiments. Data was evaluated using
ImageJ software (http://rsbweb.nih.gov/ij/).
SDS-PAGE and immunoblotting
Cells were lysed with boiling Laemmli buffer and lysates were
homogenized by passages through a 26-gauge needle. An equal
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on a SDS-polyacrylamide (10%) gel. Samples separated by SDS-
PAGE were transferred to nitrocellulose membrane (Amersham)
and blocked in phosphate saline buffer containing 5% dried milk,
washed with Tris-buffered saline containing 0.1% Tween20
(TBST), incubated with primary antibodies diluted in TBST
overnight at room temperature, then washed 5 times for 10 min,
and incubated for 1 h at room temperature with HRP-protein A
diluted in TBST. After membrane washing in TBST, the specific
signal was detected by enhanced chemiluminescence.
Specificity of the anti-SV2A antibodies was tested using lysate
from SV2A-transfected cells (Santa Cruz). The lysate (10 mg) was
run on a 10% SDS-PAGE, transferred on nitrocellulose, and
blotted with anti-SV2A, anti-SV2B, anti-SV2C, and anti-SV2C-
L4 antibodies. The specificity of anti-SV2B and anti-SV2C
antibodies was tested on rat brain extract by competition with
peptides, which had been used for immunization. Rat brain
extract (5 mg, Santa Cruz) was run on a 10% SDS-PAGE,
transferred on nitrocellulose, and blotted with anti-SV2B or anti-
SV2C antibodies preincubated or not with the indicated SV2B or
SV2C peptides (10 mg, Synaptic System) for 30 min at room
temperature.
Statistics
Values in the text are expressed as the mean 6 SD, unless
otherwise indicated. Differences between means were tested using
Student’s t-test, and p-values,0.05 were taken to indicate
significance.
Supporting Information
Figure S1 Specificity of the anti-SV2 antibodies tested by
Western blot. (A) In lysate of cells overexpressing SV2A, the
corresponding 75–80 kDa band was detected with anti-SV2A, but
not with anti-SV2B, anti-SV2C, and anti-SV2C-L4 antibodies. (B)
In rat brain extract, a band corresponding to SV2B was detected
with anti-SV2B antibodies alone or pre-incubated with SV2C
peptide. No band was observed when anti-SV2B antibodies were
preincubated with SV2B peptide. Conversely, a band correspond-
ing to SV2C was detected in rat brain lysate with anti-SV2C
antibodies alone or pre-incubated with SV2B, but to a much lower
extent when antibodies were pre-incubated with SV2C peptide.
(TIF)
Figure S2 Immuno-detection of BoNT/A (10
5 LD50/ml)
injected into the lumen of a ligated ileal segment (4 h incubation)
using antibodies against HcA. BoNT/A (green) was detected in
filament structures of the musculosa co-labeled with anti-NF (blue)
and anti-ChAT (red), showing that BoNT/A, injected in the
intestinal lumen, reached cholinergic nerve endings in the
musculosa. (scale bar=20 mm).
(TIF)
Figure S3 Immunolabeling pattern of SV2C in intestinal
submucosa. (A) HcA (red) was injected into the lumen of a ligated
intestinal loop and incubated for 1 h at room temperature. A
network of thin cell extensions around microvessels in the
submucosa were stained with anti-SV2C (green), and not with
HcA. HcA only decorated some filament extremities. (B) Thin
neuronal extensions around microvessels were labeled with anti-
neurofilament (NF, blue) and anti-SV2C (red) antibodies. (C) Glial
cells in the submucosa were stained with anti-GFAP (green) and
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